CoChat

Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis

Open access
Squire, Peter, Naude, James, Zentner, Ali, Bittman, Jesse, Khan, Nadia · 2025 · BMJ Open
Cited by 47

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Objectives: The response to glucagon-like peptide-1 (GLP-1) analogues for weight loss varies significantly. We investigated the anthropometric, demographic and clinical characteristics associated with total body weight loss (TBWL) from subcutaneous GLP-1 analogue therapy in patients with obesity in a real-world setting. Design: Retrospective cohort analysis. Setting: An urban, multidisciplinary obesity community clinic in Vancouver, Canada, from November 2018 to April 2021. Participants: 483 adults with a body mass index (BMI) of ≧30 kg/m 2 who had filled a new prescription for subcutaneous semaglutide or liraglutide, with at least 6-month follow-up, were included (mean follow-up: 17.3 months). Individuals with prior bariatric surgery were excluded. Outcomes: The primary outcome was the %TBWL over a mean follow-up period of 520 days. Participant’s TWBL was categorised as non-response (<5% TBWL), moderate response (5%–15% TBWL) or hyper-response (>15% TBWL). Results: The average %TBWL in the cohort was 12.2%. Among the participants, 17.8% had a non-response, 48.4% had a moderate response and 33.8% had a hyper-response. In the multivariable regression analysis, being a woman was associated with hyper-response (adjusted OR 1.92, CI 1.01 to 3.65, p=0.048). Age, diabetes status, baseline BMI, being sedentary, anxiety and depression were not independently associated with TBWL in response to GLP-1 analogue therapy. Conclusions: In a real-world setting, female sex was found to be associated with a hyper-response to GLP-1 analogue therapy for obesity management. Other clinical factors evaluated, including diabetes status, were not associated with the response. Future research should assess additional variables and support the development of novel biomarkers that are associated with weight loss response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2024-089477

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 47

Metadata

Authors
Squire, P., Naude, J., Zentner, A., Bittman, J., & Khan, N.
Venue
BMJ Open
Publisher
BMJ
Published
2025-01
Volume
15
Issue
1
Pages
e089477
ISSN
2044-6055 (ISSN-L)
OpenAlex
W4406426506
Cited by
47
References
21
FWCI
22.84
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2024-089477
The paper
Squire, P., Naude, J., Zentner, A., Bittman, J., & Khan, N. (2025). Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2024-089477

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.